Drug Type CAR-T |
Synonyms- |
Target |
Mechanism CD22 modulators(CD22 modulators), T lymphocyte replacements |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Lymphoblastic Leukemia | Phase 2 | - | 01 Feb 2020 | |
B-Cell Lymphoma | Phase 2 | - | 01 Feb 2020 | |
B-Cell Malignant Neoplasm | Phase 2 | - | 01 Feb 2020 | |
Chronic Lymphocytic Leukemia | Phase 2 | - | 01 Feb 2020 | |
Leukemia | Phase 2 | - | 01 Feb 2020 | |
Lymphoma | Phase 2 | - | 01 Feb 2020 |